Results 81 to 90 of about 20,522 (204)

The effect of ezetimibe on NAFLD

open access: yes, 2015
NAFLD has become the most common liver disorder in countries, where obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome are common. The strong association between these conditions and the risk of cardiovascular disease make treatment ...
AVERNA, Maurizio
core   +1 more source

Association of GLP‐1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real‐World Claims Database Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10037-10044, November 2026.
ABSTRACT Aims Large‐scale clinical trials have shown multiple effects of glucagon‐like peptide 1 receptor agonists (GLP‐1RAs); however, similar evidence for Asian patients is limited. Therefore, using a Japanese large‐scale claims‐based database, the effects of GLP‐1RAs on cardiovascular and cerebrovascular events including mortality were compared with
Masaya Koshizaka   +7 more
wiley   +1 more source

Ezetimibe therapy: mechanism of action and clinical update

open access: yes, 2012
Binh An P Phan,1 Thomas D Dayspring,2 Peter P Toth31Division of Cardiology, Loyola University Medical Center, Maywood, IL, USA; 2Foundation for Health Improvement and Technology, Wayne, NJ, USA; 3CGH Medical Center, Sterling, IL, USAAbstract: The ...
Toth PP, Dayspring TD, Phan BAP
core  

Ezetimibe Blocks Internalization of the NPC1L1/Cholesterol Complex

open access: yes, 2008
Niemann-Pick C1-like 1 (NPC1L1) is a target for ezetimibe, a drug that blocks intestinal cholesterol absorption. A new study by Ge et al. (2008) in this issue of Cell Metabolism shows that non-lipoprotein-bound cholesterol induces endocytosis of NPC1L1 ...
Chang, Ta-Yuan, Chang, Catherine
core   +1 more source

Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II) [PDF]

open access: yes, 2017
The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab has been shown to substantially reduce low-density lipoprotein cholesterol (LDL-C).
Mahfouz El Shahawy   +17 more
core   +1 more source

Lipoprotein(a), Endothelial Dysfunction and Cardiovascular Disease

open access: yesJournal of Cellular and Molecular Medicine, Volume 30, Issue 21, November 2026.
ABSTRACT Lipoprotein(a) (Lp(a)) is a particle similar to low‐density lipoprotein cholesterol and is associated with apolipoprotein (A). High Lp(a) levels are a genetic, independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Endothelial cells, which form the continuous lining of the cardiovascular system, are crucial for vascular ...
Xianghui Zhou   +5 more
wiley   +1 more source

Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 11, Page 1956-1966, November 2026.
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara   +9 more
wiley   +1 more source

Combination therapy in cholesterol reduction: focus on ezetimibe and statins

open access: yes, 2008
Liliana Grigore1, Giuseppe Danilo Norata1,2, Alberico L Catapano1,21Department of Pharmacological Sciences, University of Milan, Milan, Italy; 2Center for the Study of Atherosclerosis, Bassini Hospital, Cinisello B, ItalyAbstract: Although widely used in
Liliana Grigore   +5 more
core  

Combined Effects of Ezetimibe and Phytosterols on Cholesterol Metabolism

open access: yes, 2011
Background— Both ezetimibe and phytosterols inhibit cholesterol absorption. We tested the hypothesis that the combination of ezetimibe and phytosterols is more effective than ezetimibe alone in altering cholesterol metabolism.
Xiaobo Lin   +6 more
core   +1 more source

Ezetimibe Alone Reduces Low‐Density Lipoprotein Cholesterol in HIV‐Infected Patients Receiving Combination Antiretroviral Therapy [PDF]

open access: yes, 2008
In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with human immunodeficiency virus infection, the mean changes in low-density lipoprotein cholesterol were -5.3% (-11 mg/dL) and + 5.5% (+ 4 mg/ dL) with ezetimibe ...
Napravnik, Sonia   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy